Arrowhead reports fiscal Q3 2026 results with plozasiran Phase 3 data and Madrigal deal
Arrowhead reported topline Phase 3 results for plozasiran in severe hypertriglyceridemia and disclosed a PNPLA3 licensing deal with Madrigal worth up to $975 million in milestones.
SEC filing